$VRTX (Vertex Pharmaceuticals Incorporated)

$VRTX {{ '2016-01-27T22:40:19+0000' | timeago}} • Webcast

Boston, Massachusetts-based $VRTX said that it expects to increase the number of people eligible for Kalydeco and Orkambi drugs in 2016 through label expansion efforts. $VRTX added that it is awaiting for US FDA's approval of cystic fibrosis drug Kalydeco in people with CF ages 2 and older who have certain residual function mutations.

$VRTX {{ '2017-07-26T20:38:11+0000' | timeago}} • Announcement

$VRTX also reviewed its recent progress toward treating all people with cystic fibrosis, including the completion of an asset purchase agreement with Concert Pharmaceuticals for worldwide development and commercialization rights to CTP-656 and other assets related to the treatment of cystic fibrosis.

$VRTX {{ '2017-07-26T20:36:21+0000' | timeago}} • Announcement

$VRTX lifted 2017 non-GAAP combined research & development and selling, general & administrative expenses outlook to $1.33-1.36Bil from $1.25-1.30Bil, and GAAP combined R&D and SG&A expenses estimate to $1.79-1.92 from $1.55-1.70. The updated forecast reflects the progression of the company's cystic fibrosis portfolio.

$VRTX {{ '2017-07-26T20:33:48+0000' | timeago}} • Announcement

$VRTX expects 2017 total cystic fibrosis product revenue of $1.84-2.07Bil, comprised of Orkambi and Kalydeco product revenues. $VRTX still expects 2017 product revenue for Orkambi of $1.1-1.3Bil and for Kalydeco of $740-770MM.

$VRTX {{ '2017-07-26T20:30:18+0000' | timeago}} • Announcement

$VRTX's net product revenues from cystic fibrosis therapy Orkambi for 2Q17 increased to $324.4MM from $245.5MM last year. This was primarily driven by the continued uptake in the medicine globally and additional uptake in people with cystic fibrosis ages 6 to 11 in the U.S., where approval was received in September 2016.

$VRTX {{ '2017-07-26T20:26:38+0000' | timeago}} • Announcement

$VRTX reported net income for 2Q17 of $31.17MM or $0.07 per share compared to a loss of $64.53MM or $0.26 per share last year. This swing in results was driven by higher revenue as well as a decline in interest expenses. Revenue grew to $544.14MM from $431.61MM. Non-GAAP EPS increased to $0.39 from $0.24.

$VRTX {{ '2017-07-25T21:51:58+0000' | timeago}} • Announcement

$VRTX and $CNCE completed an asset purchase agreement, under which $VRTX gained worldwide development and commercialization rights to CTP-656 and other assets related to the treatment of cystic fibrosis. $CNCE received $160MM in cash upon closing and is eligible to receive up to $90MM in additional milestones.

$VRTX {{ '2017-07-13T12:31:35+0000' | timeago}} • Announcement

$VRTX announced that the Italian Medicines Agency has agreed to reimburse ORKAMBI (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older who have two copies of the F508del mutation. Effective immediately, hundreds of eligible patients in Italy will have access to this medicine.

$VRTX {{ '2017-06-09T09:55:40+0000' | timeago}} • Announcement

$VRTX shareholders have elected Alan M Garber as an independent member of its board of directors. Garber is provost of Harvard University, the Mallinckrodt Professor of Health Care Policy at Harvard Medical School, a Professor of Economics in the Faculty of Arts and Sciences and a Professor of Public Policy in the Harvard Kennedy School of Govt.

$VRTX {{ '2017-05-18T12:30:41+0000' | timeago}} • Announcement

$VRTX said the U.S. Food and Drug Administration has approved Kalydeco (ivacaftor) for use in people with cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator gene. $VRTX lifted outlook for 2017 product revenue of Kalydeco to $740-770MM from $710-730MM.

$VRTX {{ '2017-04-27T21:59:58+0000' | timeago}} • Webcast

In March 2017, $VRTX agreed to acquire CTP-656 (a therapy for the treatment of cystic fibrosis) from Concert Pharmaceuticals in a $160MM deal. The company is in the review period now and it has withdrawn and refiled pre-merger notification with the U.S. regulatory authorities.

$VRTX {{ '2017-04-27T21:35:40+0000' | timeago}} • Webcast

For 2017, $VRTX said that there is an uncertainty, mainly related to the timing of reimbursements in Europe. In France, there is an uncertainty because of the election. However, France is the largest contributor outside the U.S. for the company's 2017 revenues.

$VRTX {{ '2017-04-27T21:16:31+0000' | timeago}} • Webcast

$VRTX said that it is evaluating four next-generation correctors (VX-152, VX-440, VX-659 and VX-445), which will help in treating cystic fibrosis. The company expects to have data from the studies for the first three in 1H17 and from the fourth one in early 2018.

$VRTX {{ '2017-04-27T20:35:56+0000' | timeago}} • Announcement

$VRTX reiterated its FY17 guidance for ORKAMBI revenues and increased the guidance for KALYDECO. The company expects ORKAMBI FY17 total product revenues to be about $1.1-1.3Bil and increased FY17 product revenue guidance for KALYDECO to $710-730MM, from $690-710MM.

$VRTX {{ '2017-04-27T20:32:19+0000' | timeago}} • Announcement

Pharma company $VRTX reported 1Q17 net income of $247.8MM, or $0.99 per share, compared to net loss of $41.6MM, or $0.17 per share during 1Q16. On non-GAAP basis, $VRTX earned $0.41 per share. Revenue increased 79.5% to $714.7MM, helped by increased net product revenues from ORKAMBI.

$VRTX {{ '2017-03-29T11:23:47+0000' | timeago}} • Announcement

$VRTX posted that Tezacaftor/Ivacaftor combination treatment met primary endpoints in two phase 3 studies, regarding the treatment of people with cystic fibrosis. Vertex plans to submit a new drug application to the FDA and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in 3Q17.

$SNH {{ '2017-03-27T14:26:05+0000' | timeago}} • Announcement

The property included in the new JV with a sovereign institutional investor was acquired by $SNH in May 2014 for $1.125Bil. The two buildings are 95% leased to $VRTX through 2028. SNH expects to use cash proceeds from this transaction to repay a portion of the amounts outstanding under its revolving credit facility.

$VRTX {{ '2017-03-06T14:33:44+0000' | timeago}} • Announcement

$VRTX announced it signed a definitive asset purchase agreement to acquire CTP-656, including all worldwide development and commercialization rights, from $CNCE for $160MM in cash. Concert was initially developing CTP-656 as a potential treatment for cystic fibrosis.

$VRTX {{ '2017-01-25T21:43:59+0000' | timeago}} • Announcement

$VRTX expects 2017 product revenue for ORKAMBI to be in the range of $1.1-1.3Bil and for KALYDECO to be in the range of $690-710MM.

$VRTX {{ '2017-01-25T21:43:43+0000' | timeago}} • Announcement

For 4Q16, $VRTX reported a 13.5% YoverY revenue growth in its CF product, helped by the 26% revenue increase from ORKAMBI. Net product revenue from KALYDECO fell 2% in the quarter.

$VRTX {{ '2017-01-25T21:32:00+0000' | timeago}} • Announcement

Pharma company $VRTX reported 4Q16 net income of $32.9MM, or $0.13 per diluted share, compared to net loss of $73.7MM, or $0.30 per diluted share, in the prior year quarter. On a non-GAAP basis, the company earned $0.35 per diluted share, an increase of 94% YoverY. Revenue rose 9.7% to $458.7MM for the quarter.

Recent Transcripts

BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, July 26 2017 - 9:15pm
TMO (Thermo Fisher Scientific, Inc.)
Wednesday, July 26 2017 - 12:30pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
JNJ (Johnson & Johnson)
Tuesday, July 18 2017 - 12:30pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
CCXI (ChemoCentryx, Inc.)
Wednesday, May 10 2017 - 9:00pm
ARRY (Array BioPharma Inc.)
Wednesday, May 10 2017 - 1:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
OPK (Opko Health, Inc.)
Tuesday, May 9 2017 - 8:30pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
ARQL (ArQule Inc.)
Wednesday, May 3 2017 - 1:00pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
RIGL (Rigel Pharmaceuticals, Inc.)
Tuesday, May 2 2017 - 9:00pm
PFE (Pfizer Inc.)
Tuesday, May 2 2017 - 2:00pm
EXEL (Exelixis, Inc.)
Monday, May 1 2017 - 9:00pm
VRTX (Vertex Pharmaceuticals Incorporated)
Thursday, April 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm

AlphaGraphics you may like